BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 27556158)

  • 1. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer.
    Jiang G; Zhang S; Yazdanparast A; Li M; Pawar AV; Liu Y; Inavolu SM; Cheng L
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):525. PubMed ID: 27556158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive molecular portraits of human breast tumours.
    Cancer Genome Atlas Network
    Nature; 2012 Oct; 490(7418):61-70. PubMed ID: 23000897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering the Correlation between Breast Tumor Samples and Cell Lines by Integrating Copy Number Changes and Gene Expression Profiles.
    Sun Y; Liu Q
    Biomed Res Int; 2015; 2015():901303. PubMed ID: 26273658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.
    Aure MR; Vitelli V; Jernström S; Kumar S; Krohn M; Due EU; Haukaas TH; Leivonen SK; Vollan HK; Lüders T; Rødland E; Vaske CJ; Zhao W; Møller EK; Nord S; Giskeødegård GF; Bathen TF; Caldas C; Tramm T; Alsner J; Overgaard J; Geisler J; Bukholm IR; Naume B; Schlichting E; Sauer T; Mills GB; Kåresen R; Mælandsmo GM; Lingjærde OC; Frigessi A; Kristensen VN; Børresen-Dale AL; Sahlberg KK;
    Breast Cancer Res; 2017 Mar; 19(1):44. PubMed ID: 28356166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
    Kao J; Salari K; Bocanegra M; Choi YL; Girard L; Gandhi J; Kwei KA; Hernandez-Boussard T; Wang P; Gazdar AF; Minna JD; Pollack JR
    PLoS One; 2009 Jul; 4(7):e6146. PubMed ID: 19582160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterisation of cell line models for triple-negative breast cancers.
    Grigoriadis A; Mackay A; Noel E; Wu PJ; Natrajan R; Frankum J; Reis-Filho JS; Tutt A
    BMC Genomics; 2012 Nov; 13():619. PubMed ID: 23151021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
    Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
    Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
    Riaz M; van Jaarsveld MT; Hollestelle A; Prager-van der Smissen WJ; Heine AA; Boersma AW; Liu J; Helmijr J; Ozturk B; Smid M; Wiemer EA; Foekens JA; Martens JW
    Breast Cancer Res; 2013 Apr; 15(2):R33. PubMed ID: 23601657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype-specific accumulation of intracellular zinc pools is associated with the malignant phenotype in breast cancer.
    Chandler P; Kochupurakkal BS; Alam S; Richardson AL; Soybel DI; Kelleher SL
    Mol Cancer; 2016 Jan; 15():2. PubMed ID: 26728511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
    Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
    Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
    Bergamaschi A; Kim YH; Wang P; Sørlie T; Hernandez-Boussard T; Lonning PE; Tibshirani R; Børresen-Dale AL; Pollack JR
    Genes Chromosomes Cancer; 2006 Nov; 45(11):1033-40. PubMed ID: 16897746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
    Saunus JM; Smart CE; Kutasovic JR; Johnston RL; Kalita-de Croft P; Miranda M; Rozali EN; Vargas AC; Reid LE; Lorsy E; Cocciardi S; Seidens T; McCart Reed AE; Dalley AJ; Wockner LF; Johnson J; Sarkar D; Askarian-Amiri ME; Simpson PT; Khanna KK; Chenevix-Trench G; Al-Ejeh F; Lakhani SR
    Breast Cancer Res Treat; 2018 Jan; 167(1):289-301. PubMed ID: 28889351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
    Pink JJ; Jordan VC
    Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coupling proteomics and transcriptomics in the quest of subtype-specific proteins in breast cancer.
    Pavlou MP; Dimitromanolakis A; Diamandis EP
    Proteomics; 2013 Apr; 13(7):1083-95. PubMed ID: 23386393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database.
    Hwang KT; Kim K; Chang JH; Oh S; Kim YA; Lee JY; Jung SH; Choi IS
    Cancer Res Treat; 2018 Jul; 50(3):658-669. PubMed ID: 28701032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.
    Pfefferle AD; Agrawal YN; Koboldt DC; Kanchi KL; Herschkowitz JI; Mardis ER; Rosen JM; Perou CM
    Dis Model Mech; 2016 Jul; 9(7):749-57. PubMed ID: 27149990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.
    Berg KCG; Eide PW; Eilertsen IA; Johannessen B; Bruun J; Danielsen SA; Bjørnslett M; Meza-Zepeda LA; Eknæs M; Lind GE; Myklebost O; Skotheim RI; Sveen A; Lothe RA
    Mol Cancer; 2017 Jul; 16(1):116. PubMed ID: 28683746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
    She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
    BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.
    Li D; Xia H; Li ZY; Hua L; Li L
    Biomed Res Int; 2015; 2015():746970. PubMed ID: 25961039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.